



US005961952A

United States Patent [19]

Crane et al.

[11] Patent Number: **5,961,952**
 [45] Date of Patent: **Oct. 5, 1999**

[54] ^{99m}Tc-TERTIARY-BUTYL ISONITRILE AS
BREAST TUMOR IMAGING AGENTS

[75] Inventors: Paul David Crane, Lincoln; David
Charles Onthank, Billerica; Milind
Rajopadhye, Westford, all of Mass.

[73] Assignee: DuPont Pharmaceuticals Company,
Wilmington, Del.

[21] Appl. No.: 08/785,399

[22] Filed: Jan. 23, 1997

Related U.S. Application Data

[60] Provisional application No. 60/010,516, Jan. 24, 1996.

[51] Int. Cl.⁶ A61K 51/00; A61M 36/14

[52] U.S. Cl. 424/1.65; 534/14; 424/9.1;
424/1.11

[58] Field of Search 424/1.11, 1.65,
424/9.1, 9.3, 9.4, 9.5, 9.6; 534/7, 10-16;
206/223, 569, 570

References Cited

U.S. PATENT DOCUMENTS

| | | | |
|-----------|---------|----------------------------|----------|
| 4,452,774 | 6/1984 | Jones et al. . | |
| 4,707,544 | 11/1987 | Jones et al. | 534/14 |
| 4,826,961 | 5/1989 | Jones et al. | 534/14 |
| 4,894,445 | 1/1990 | Carpenter, Jr. et al. | 534/14 |
| 4,988,827 | 1/1991 | Bergstein et al. . | |
| 5,081,232 | 1/1992 | Latham et al. | 534/14 |
| 5,167,948 | 12/1992 | Wenzel | 424/1.11 |
| 5,279,811 | 1/1994 | Bergstein et al. . | |
| 5,324,824 | 6/1994 | Carpenter et al. . | |

FOREIGN PATENT DOCUMENTS

| | | |
|-----------|--------|----------------------|
| 0183555 | 6/1986 | European Pat. Off. . |
| WO9206685 | 4/1992 | WIPO . |

OTHER PUBLICATIONS

P. Ramanathan, R.B. Patel, N. Subrahmanyam, U.N. Nayak,
S.S. Sachdev and N. Ramamoorthy, *The Journal of Nuclear
Medicine* 1990, 31(7), 1163-1165, "Visualization of Sup-

pressed Thyroid Tissue by Technetium-99m-Tertiary Butyl
Isonitrile: An Alternative to Post-TSH Stimulation Scan-
ning".

Crane et al, *Journal Of Nuclear Medicine*, 1994, 35(5), 21P,
"Tc-99m-Sestamibi Retention In The C-Neu Oncomouse:
An In Vivo Model For Breast Tumor Imaging".

Piwnica-Worms et al, *Journal of Nuclear Medicine*, 1990,
31(7), 1166-1167, "Noncardiac Applications of Hexakis-
(Alkylisonitrile) Technetium-99m Complexes".

Sachdev et al, *Nuclear Medicine Biology*, 1990, 17(6),
543-552, "Preparation and Evaluation of ^{99m}Tc-t-Butyl-
isonitrile (^{99m}Tc-TBI) for Myocardial Imaging: a Kit for
Hospital Radiopharmacy".

Bouquillon et al (1995), *Nucl. Med. Biol.*, vol. 22, No. 5, pp.
585-588, "Synthesis Characterization and Biodistribution of
a New Technetium-99m Complex with Trimethylsilylmeth-
ylisonitrile. Comparison with 99m Tc-TBI and 99m-Tc-
MIBI".

Rochon et al (1996), *Inorganica Chimica Acta*, vol. 245, pp.
251-256 "Synthesis and Crystal Structure of Mixed-Ligand
Tc(I) Complexes, with Dimethyphenylphosphine and T-Bu-
tylisonitrile".

Dox et al (1993), *The Harper Collins Illustrated Medical
Dictionary*, p. 494 & "Tumor" and p. 301, "Neoplasm".

Primary Examiner—Jose' G. Dees

Assistant Examiner—Dameron Jones

Attorney, Agent, or Firm—David H. Vance

[57] ABSTRACT

A novel method of diagnosing or radioimaging breast
tumors using ^{99m}Tc- or ^{186/188}Re-tertiary-butyl isonitrile
complex and a kit for diagnosing or radioimaging breast
tumors containing tertiary-butyl isonitrile and a solubiliza-
tion aid are presented.

40 Claims, No Drawings

PLEASE
SCAN

^{99m}Tc-TERTIARY-BUTYL ISONITRILE AS BREAST TUMOR IMAGING AGENTS

This application claims the benefit of U.S. Provisional Application Ser. No. 60/010,516, filed Jan. 24, 1996.

FIELD OF THE INVENTION

The present invention relates generally to a method of using ^{99m}Tc-tertiary-butyl isonitrile complex and its analogs as breast tumor diagnosing or imaging agents and a kit for diagnosing or imaging breast tumors.

BACKGROUND OF THE INVENTION

Several studies have reported the use of ^{99m}Tc-sestamibi (mibi=CNCH₂C(CH₃)₂(OCH₃)) for imaging various tumors including breast, Clin. Nucl. Med. 17:171-176, thyroid, parathyroid, bone, lung and brain. ^{99m}Tc-sestamibi appears to have a high sensitivity (>90%) and acceptable specificity (>70%) for imaging breast tumors, J. Nucl. Med. 1993, 34:149P. ^{99m}Tc-sestamibi localizes within the mitochondria of tissues and the mechanism appears to be the attraction of the lipophilic cationic complex to the negative potential on the inner mitochondrial membrane. ^{99m}Tc-sestamibi is retained in human tumors and is currently in clinical trial as a diagnostic agent for imaging of breast tumors.

^{99m}Tc-tertiary-butyl isonitrile complex (^{99m}Tc-TBI) has previously been described in U.S. Pat. No. 4,452,774 (Jones et al) and U.S. Pat. No. 4,988,827 (Bergstein et al). In Example 5 of Bergstein et al, it was shown that ^{99m}Tc-TBI is an inferior myocardial imaging agent compared with the ether isonitriles described therein due to ^{99m}Tc-TBI's low heart/liver and heart/lung uptake ratios. Bergstein et al did not test for tumor imaging agents and did not suggest using ^{99m}Tc-TBI or ^{186/188}Re-TBI as a breast tumor imaging agent.

Ramanathan et al, J. Nucl. Med. 1990, 31(7), 1163, indicate that ^{99m}Tc-TBI can be used to image a suppressed thyroid lobe in place of the thyrotropin stimulation test. However, there is no mention in this article of using ^{99m}Tc-TBI as a tumor imaging agent.

Even though ^{99m}Tc-sestamibi is an excellent tumor imaging agent, other agents providing enhanced sensitivity and specificity in tumor imaging could significantly impact on patient care. This would translate to detecting smaller (earlier) tumors and/or better resolution in difficult-to-image patients. The vast number of patients diagnosed with tumors provides the impetus for finding imaging agents which provide greater uptake and retention compared with those presently known.

SUMMARY OF THE INVENTION

Accordingly, one object of the present invention is to provide a novel method of diagnosing breast tumors using ^{99m}Tc-tertiary-butyl isonitrile complex (^{99m}Tc-TBI) or ^{186/188}Re-tertiary-butyl isonitrile complex (^{186/188}Re-TBI). Another object of the present invention is to provide a novel method of radioimaging breast tumors using ^{99m}Tc-tertiary-butyl isonitrile complex (^{99m}Tc-TBI) or ^{186/188}Re-tertiary-butyl isonitrile complex (^{186/188}Re-TBI).

Another object of the present invention is to provide a novel kit for diagnosing or radioimaging breast tumors containing tertiary-butyl isonitrile, a solubilization aid, and a reducing agent capable of reducing either ^{99m}Tc or ^{186/188}Re to form ^{99m}Tc-TBI complex or ^{186/188}Re-TBI complex.

These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that ^{99m}Tc-TBI is an excellent breast tumor imaging agent.

DETAILED DESCRIPTION OF THE INVENTION

Thus, in a first embodiment, the present invention provides a method of diagnosing breast tumors, comprising:

- (a) administering parenterally to a mammal an effective amount of a composition comprising an imaging agent selected from ^{99m}Tc-tertiary-butyl isonitrile complex and ^{186/188}Re-tertiary-butyl isonitrile complex and a pharmaceutically acceptable carrier; and,
- (b) radioimaging the mammal to determine whether a breast tumor is present.

In a preferred embodiment, the imaging agent is ^{99m}Tc-tertiary-butyl isonitrile complex.

In a another preferred embodiment, the imaging agent is ^{186/188}Re-tertiary-butyl isonitrile complex.

In another preferred embodiment, the composition has an activity of from about 1 to 100 mCi.

In a more preferred embodiment, the composition has an activity of from about 5 to 50 mCi.

In a another preferred embodiment, the pharmaceutical carrier is saline.

In a another preferred embodiment, the pharmaceutical carrier is water.

In another preferred embodiment, the composition contains a pharmaceutically acceptable filler.

In another more preferred embodiment, the filler is mannitol.

In another preferred embodiment, the composition used is formed from a sterile, non-pyrogenic, kit, comprising:

- (a) a predetermined quantity of tertiary-butyl isonitrile;
- (b) a solubilization aid; and,
- (c) a predetermined quantity of a reducing agent.

In another more preferred embodiment, the solubilization aid (b) is selected from glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monooleate, polysorbates, poly(oxyethylene) poly(oxypropylene) poly(oxyethylene) block copolymers (Pluronic), and lecithin.

In an even more preferred embodiment, the solubilization aid (b) is selected from polyethylene glycol and Pluronic.

In a further preferred embodiment, the solubilization aid (b) is polyethylene glycol.

In another more preferred embodiment, the tertiary-butyl isonitrile (a) is in the form of a metal complex, wherein said metal is selected from Cu, Mo, Pd, Co, Ni, Cr, Ag, Rh and Zn.

In another even more preferred embodiment, the metal is Cu.

In another more preferred embodiment, the reducing agent (c) is stannous chloride.

In another more preferred embodiment, components (a), (b), and (c) are contained in a vial.

In another even more preferred embodiment, the vial contains a pharmaceutically acceptable filler.

In another further preferred embodiment, the filler is mannitol.

In a still further preferred embodiment, components (a), (b), (c), and the filler are lyophilized.

In a second embodiment, the present invention provides a method of radioimaging breast tumors, comprising:

- (a) administering parenterally to a mammal an effective amount of a composition comprising an imaging agent

selected from ^{99m}Tc -tertiary-butyl isonitrile complex and $^{186/188}\text{Re}$ -tertiary-butyl isonitrile complex and a pharmaceutically acceptable carrier; and,

(b) radioimaging the mammal after allowing sufficient time for the composition to localize in a breast tumor present in the mammal.

In a preferred embodiment, the imaging agent is ^{99m}Tc -tertiary-butyl isonitrile complex.

In another preferred embodiment, the imaging agent is $^{186/188}\text{Re}$ -tertiary-butyl isonitrile complex.

In another preferred embodiment, the composition has an activity of from about 1 to 100 mCi.

In a more preferred embodiment, the composition has an activity of from about 5 to 50 mCi.

In another preferred embodiment, the pharmaceutical carrier is saline.

In another preferred embodiment, the pharmaceutical carrier is water.

In another preferred embodiment, the composition contains a pharmaceutically acceptable filler.

In another more preferred embodiment, the filler is mannitol.

In another preferred embodiment, the composition used is formed from a sterile, non-pyrogenic, kit, comprising:

(a) a predetermined quantity of tertiary-butyl isonitrile;

(b) a solubilization aid; and,

(c) a predetermined quantity of a reducing agent.

In another more preferred embodiment, the solubilization aid (b) is selected from glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monooleate, polysorbates, poly(oxyethylene) poly(oxypropylene) poly(oxyethylene) block copolymers (Pluronic), and lecithin.

In an even more preferred embodiment, the solubilization aid (b) is selected from polyethylene glycol and Pluronic.

In a further preferred embodiment, the solubilization aid (b) is polyethylene glycol.

In another more preferred embodiment, the tertiary-butyl isonitrile (a) is in the form of a metal complex, wherein said metal is selected from Cu, Mo, Pd, Co, Ni, Cr, Ag, Rh and Zn.

In another even more preferred embodiment, the metal is Cu.

In another more preferred embodiment, the reducing agent (c) is stannous chloride.

In another more preferred embodiment, components (a), (b), and (c) are contained in a vial.

In another even more preferred embodiment, the vial contains a pharmaceutically acceptable filler.

In another further preferred embodiment, the filler is mannitol.

In a still further preferred embodiment, components (a), (b), (c), and the filler are lyophilized.

In a third embodiment, the present invention provides a sterile, non-pyrogenic, kit for diagnosing or radioimaging breast tumors, comprising:

(a) a predetermined quantity of tertiary-butyl isonitrile;

(b) a solubilization aid; and,

(c) a predetermined quantity of a reducing agent.

In a preferred embodiment, the solubilization aid (b) is selected from glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monooleate, polysorbates, poly(oxyethylene) poly(oxypropylene) poly(oxyethylene) block copolymers (Pluronic), and lecithin.

In a more preferred embodiment, the solubilization aid (b) is selected from polyethylene glycol and Pluronic.

In an even more preferred embodiment, the solubilization aid (b) is polyethylene glycol.

In another preferred embodiment, the tertiary-butyl isonitrile (a) is in the form of a metal complex, wherein said metal is selected from Cu, Mo, Pd, Co, Ni, Cr, Ag, Rh and Zn.

In a more preferred embodiment, the metal is Cu.

In another preferred embodiment, the reducing agent (c) is stannous chloride.

In another preferred embodiment, components (a), (b), and (c) are contained in a vial.

In another more preferred embodiment, the vial contains a pharmaceutically acceptable filler.

In a further preferred embodiment, the filler is mannitol.

In a still further preferred embodiment, components (a), (b), (c), and the filler are lyophilized.

As used herein ^{99m}Tc -TBI is intended to represent the complex, $^{99m}\text{Tc}(\text{TBI})_6^+$, formed by reduction of a ^{99m}Tc species in the presence of TBI. ^{99m}Tc -TBI is considered to be associated with anions present in the composition to achieve a charge neutral salt. One of ordinary skill in the art would recognize the anion(s) present depends upon the pharmaceutical carrier, the reductant used, and the presence of optional components selected from buffers, stabilization aids and lyophilization aids. If saline, for example, was used as the pharmaceutical carrier, then chloride (Cl^-) would be the counterion. Other anions include, but are not limited to, sulphate, acetate, phosphate, citrate, succinate and tartrate.

As used herein $^{186/188}\text{Re}$ -TBI is intended to represent the $^{186/188}\text{Re}$ -TBI complex formed by reduction of a $^{186/188}\text{Re}$ species in the presence of TBI. As with ^{99m}Tc -TBI, $^{186/188}\text{Re}$ -TBI is considered to be associated with enough counterions necessary to achieve a charge neutral complex.

The present radiolabeled complexes are prepared by admixing TBI with a radioactive metal in suitable media at temperatures from room temperature to reflux temperatures or even higher. The labeled TBI complexes are isolable and can be obtained in high yields. The reaction is generally complete after about 1 minute to about 2 hours, depending upon the particular reagents employed and the conditions used. Reducing agents, when required or desired to speed up the reaction, are well known to those skilled in the art. Reducing agents useful in the present invention are capable of reducing a radionuclide such as Tc or Re. Examples of such well-known reducing agents include a stannous salt such as stannous chloride (often used in the form of kits), and stannous fluoride, or other suitable reducing agents such as Fe(II), Cu(I), Ti(III), or Sb(III), formamidine sulfonic acid, sodium dithionite, sodium bisulfite, hydroxylamine, ascorbic acid, sodium borohydride, and the like. The preferred reducing agent is a stannous reducing agent, more preferably, stannous chloride.

The activity of the imaging agents presently used is preferably in the range of 1 to 100 mCi, more preferably, 5 to 50 mCi. These ranges of activity are considered to be for the entire composition.

The TBI technetium complexes prepared in accord with the present invention preferably are prepared from pertechnetate, but can also be prepared from preformed technetium complexes having technetium oxidation states of, for instance, III, IV or V, by treating these preformed complexes with an excess of ligand under suitable conditions.

The TBI rhenium complexes in accord with the present invention preferably are prepared from perrhenate which is well known to those of skill in the art. Either ^{186}Re or ^{188}Re can be used interchangeably depending on the practitioner's access to the materials necessary to obtain these isotopes.

An excess of TBI up to 100 fold molar excess or more based on the amount of radionuclide, and an excess of reducing agent, preferably 10 to 20 fold molar excess or more, can be used in the complexing reaction to ensure maximum yield from the radionuclide. The amount of reducing agent present will depend on the desired shelf life of the kit as well as other factors well known to those of skill in the art. Following the reaction, the desired complex can be separated from the reaction mixture, if required, for example by crystallization, precipitation, conventional chromatography or ion exchange chromatography; see for example U.S. Pat. No. 4,452,774, the contents of which are hereby incorporated by reference.

Preferably, the radioimaging step of the present diagnostic method is performed after allowing sufficient time for the composition to localize in a breast tumor which may be present in the mammal. One of ordinary skill in the art understands that a certain amount of time is usually needed to allow a radioimaging agent to localize and the background to diminish. The amount of time necessary depends on a number of factors known to those of skill in the art.

Kits in accord with the present invention comprise a sterile, non-pyrogenic, formulation comprising TBI and, if required, a quantity of a reducing agent for reducing a preselected radionuclide, and optionally other components such as transfer ligands, buffers, lyophilization aids, stabilization aids, and bacteriostats. The inclusion of one or more optional components in the formulation will frequently improve the ease of synthesis of the radiopharmaceutical by the practicing end user, the ease of manufacturing the kit, the shelf-life of the kit, or the stability and shelf-life of the radiopharmaceutical. The improvement achieved by the inclusion of an optional component in the formulation must be weighed against the added complexity of the formulation and added cost to manufacture the kit. Preferably, kits according to the present invention contain a solubilization aid due to the inherent difficulties of manipulating TBI.

The present kits may be contained in one or more vials and all or part of the formulation can independently be in the form of a sterile solution or a lyophilized solid. It is preferred that TBI and reducing agent be lyophilized, when possible, to facilitate storage stability. Preferably a solubilization aid is present to ease removal of TBI upon reconstitution. If lyophilization is not practical, the kits can be stored frozen or in solution at room temperature. The solvents used are usually water or saline, preferably, water. Preferably, the kits are sealed.

The choice of radionuclides for diagnostic imaging will depend on the use and can be selected from radioactive isotopes Tc, Re, Ru, Co, Pt, Fe, Os, and Ir, preferably Tc or Re. Of course, because of availability of pertechnetate generators, such radionuclide is especially preferred. Due to the emission of both beta and gamma radiation, Re can be selected for both diagnostic and therapeutic purposes. The use of $^{186/188}\text{Re}$ -TBI as a therapeutic radiopharmaceutical for breast tumors is contemplated by this invention. Sterile non-pyrogenic containers (vials) which contain a predetermined quantity of sterile TBI, and a predetermined quantity of a sterile reducing agent such as stannous chloride and which are capable of reducing a predetermined quantity of a preselected radionuclide are preferred.

The TBI in the presently contemplated kits can be in the form of a non-radioactive metal adduct such as those described in U.S. Pat. No. 5,324,824, the contents of which are hereby incorporated by reference. The displaceable metals useful in the preparation of such metal-adducts are selected from the class preferably consisting of Cu, Mo, Pd,

Co, Ni, Cr, Ag, Rh and Zn, and can be readily prepared by admixing a complex of the displaceable metal and TBI in a suitable media at temperatures from room temperature to reflux temperature or even higher. The reaction is generally complete after about 1 minute to about 2 hours, depending upon the reagents employed and the conditions used.

In one embodiment of the invention, a kit for use in making the complexes of the present invention from a supply of ^{99m}Tc such as the pertechnetate solution in isotonic saline available in most clinical laboratories includes the desired quantity of TBI to react with a selected quantity of pertechnetate, and a reducing agent such as stannous chloride in an amount sufficient to reduce the selected quantity of pertechnetate to form the desired complex. In a preferred embodiment, the kit also contains a solubilization aid to aid in formation of the radioimaging complex and optionally other components such as transfer ligands, buffers, lyophilization aids, stabilization aids, and bacteriostats.

Kits according to the present invention can contain one or two vials. If two vials are used, the first vial would contain TBI, preferably a solubilization aid, and optional components selected from an inert filler, a buffer, and a stabilization aid. The second vial would contain a reductant and optional components selected from an inert filler, a buffer, and a stabilization aid such as EDTA.

A preferred kit for the facile preparation of the desired ^{99m}Tc radiopharmaceutical, in accordance with the present invention, is comprised of one vial. The vial contains TBI and a reductant suitable to convert the ^{99m}Tc to the desired oxidation state prepared in lyophilized form and, preferably, a solubilization aid and an inert filler, such as mannitol, to provide easy lyophilization. Additionally, a buffer may also be present in the vial. One method by which the ^{99m}Tc radiopharmaceutical can be prepared in high yield is as follows:

A vial may be prepared containing a sterile, non-pyrogenic, freeze-dried material comprising a copper-TBI adduct at levels of 100 μg to 2 mg, or higher, a suitable reductant, such as a stannous salt (e.g., stannous chloride and its hydrates) at levels of 5 μg to 100 μg or more, with from about 1 to 250 mg, preferably, about 5 to 100 mg, of a suitable inert filler such as, but not limited to, mannitol, to provide a suitable plug after freeze-drying and, a suitable solubilization aid, such as, but not limited to, polyethylene glycol, and, optionally a buffer, such as citrate, and optionally a stabilization aid, such as cysteine. Preferably, the amount of solubilization aid present is from about 0.01 to 10 wgt %, more preferably, from about 0.05 to 5 wgt % based on the total weight of the composition of the vial. Preferably, the amount of buffer present is from about 0.1 mg to 100 mg, more preferably from 1 mg to 10 mg. Preferably, the amount of stabilization aid present is from 0.1 mg to 10 mg, more preferably from 0.5 mg to 5 mg.

The vial can be reconstituted by aseptic introduction through the rubber stopper seal using a syringe of a ^{99m}Tc solution, preferably ^{99m}Tc -pertechnetate in saline, in the amount of 1 mCi to 1000 mCi, preferably from 10 mCi to 100 mCi, in a volume of 0.1 mL to 10 mL, preferably 1 mL to 5 mL. The vial is then allowed to react at room temperature or it is heated at temperatures up to 100° C. or higher, for 1 minute to 6 hours, preferably it is heated at 100° C. for about 1 to 30 minutes. An effective amount of the composition is withdrawn by aseptic technique using a syringe for administration to a mammal.

Solubilization aids useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monooleate, polysorbates, poly(oxyethylene) poly(oxypropylene) poly(oxyethylene) block copolymers (Pluronic) and lecithin. Preferred solubilizing aids are polyethylene glycol and Pluronic. Preferably, the polyethylene glycol and Pluronic to be used in the present kits are of a molecular weight such that they are liquids at ambient temperature or have melting points of 60° C. or lower. Preferred number average molecular weights for polyethylene glycol are between 100 and 900, more preferably, 200, 300, 400, 500, and 600. Pluronic, also termed poloxamers, have number average molecular weights between 2000 and 15,000. Preferred number average molecular weights for Pluronic are between 2000 and 9000. The chemical and physical properties of available polyethylene glycols and Pluronic can be found in the *United States Pharmacopeia, National Formulary*, volumes XVII and XVIII.

The amount of solubilization aid will depend on the amount of TBI present in the kit, and preferably, will be present in about 0.01 to 10 wgt %, more preferably, 0.05 to 5 wgt %, based on the total weight of the composition containing the solubilization aid.

Buffers useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to phosphate, citrate, sulfosalicylate, succinate, tartrate, and acetate. A more complete list can be found in the *United States Pharmacopoeia*.

Lyophilization aids useful in the preparation diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to mannitol, lactose, sorbitol, dextran, Ficoll, and polyvinylpyrrolidone (PVP).

Stabilization aids useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to ascorbic acid, cysteine, monothioglycerol, sodium bisulfite, sodium metabisulfite, gentisic acid, and inositol.

Bacteriostats useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to benzyl alcohol, benzalkonium chloride, chlorbutanol, and methyl, propyl or butyl paraben.

A component in a diagnostic kit can also serve more than one function. A reducing agent can also serve as a stabilization aid, a buffer can also serve as a transfer ligand, a lyophilization aid can also serve as a transfer ligand, and so forth.

The predetermined amounts of each component in the formulation are determined by a variety of considerations that are in some cases specific for that component and in other cases dependent on the amount of another component or the presence and amount of an optional component. In general, the minimal amount of each component is used that will give the desired effect of the formulation. The desired effect of the formulation is that the practicing end user can synthesize the radiopharmaceutical and have a high degree of certainty that the radiopharmaceutical can be safely injected into a patient and will provide diagnostic information about the disease state of that patient.

The diagnostic kits of the present invention may also contain written instructions for the practicing end user to follow to synthesize the radiopharmaceuticals. These instructions may be affixed to one or more of the vials or to

the container in which the vial or vials are packaged for shipping or may be a separate insert, termed the package insert.

A "diagnostic kit," as used herein, comprises a collection of components, which may be termed the formulation, in one or more vials which are used by the practicing end user in a clinical or pharmacy setting to synthesize the radiopharmaceutical. The kit generally provides all the requisite components to synthesize and use the radiopharmaceutical except those that are commonly available to the practicing end user may be excluded, such as water or saline for injection, a solution of the radionuclide, equipment for heating the kit during the synthesis of the radiopharmaceutical if required, equipment necessary for administering the radiopharmaceutical to the patient such as syringes and shielding, and imaging equipment.

A "buffer," as used herein, is a compound that is used to control the pH of the kit during its manufacture and during the synthesis of the radiopharmaceutical.

A "lyophilization aid," as used herein, is a component that has favorable physical properties for lyophilization, such as the glass transition temperature, and is added to the diagnostic kit to improve the physical properties of the combination of the components to be lyophilized.

A "stabilization aid," as used herein, is a component that is added to the radiopharmaceutical or to the diagnostic kit either to stabilize the radiopharmaceutical once it is synthesized or to prolong the shelf-life of the kit before it must be used. Stabilization aids can be antioxidants, reducing agents or radical scavengers and can provide improved stability by reacting preferentially with species that degrade other components or the radiopharmaceutical.

A "solubilization aid," as used herein, is a component that improves the solubility of one or more other components in the formulation used for the synthesis of the radiopharmaceutical.

A "bacteriostat," as used herein, is a component that inhibits the growth of bacteria in the diagnostic kit either during its storage before use or after the kit is used to synthesize the radiopharmaceutical.

A "reducing agent," as used herein, is a compound that reacts with a radionuclide, which is typically obtained as a relatively unreactive, high oxidation state compound, to lower its oxidation state by transferring electron(s) to the radionuclide, thereby making it more reactive. Reducing agents useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to stannous chloride, stannous fluoride, formamidine sulfinic acid, ascorbic acid, cysteine, phosphines, and cuprous or ferrous salts. Other reducing agents are described in Brodack et. al., PCT Application 94/22496, which is incorporated herein by reference.

A "transfer ligand," as used herein, is a ligand that forms an intermediate complex with the radionuclide that is stable enough to prevent unwanted side-reactions but labile enough to be converted to the radiopharmaceutical. The formation of the intermediate complex is kinetically favored while the formation of the radiopharmaceutical is thermodynamically favored. Transfer ligands useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to gluconate, glucoheptonate, mannitol, glucarate, N,N,N',N'-ethylenediaminetetraacetic acid, pyrophosphate and methylenediphosphonate. In general, transfer ligands are comprised of oxygen or nitrogen donor atoms.

Other features of the invention will become apparent in the course of the following descriptions of exemplary

embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

Preparation of Kits, Labeling and HPLC Procedure

Tertiary-butyl isonitrile (TBI), stannous chloride dihydrate, L-cysteine hydrochloride, and sodium hydrosulfite are commercially available from Aldrich Chemical Company. Other reagents and solvents can be obtained from other commercial sources.

The following protocol was observed for labeling, HPLC purification, and preparation of samples for assaying. A kit was prepared, as described below, and reconstituted with $^{99m}\text{TcO}_4^-$ in saline from a $^{99}\text{Mo}/^{99m}\text{Tc}$ radiopharmaceutical generator using sterile techniques well known to those skilled in the art for preparing sterile injection materials. Pertechnetate generators are well known in the art. Preferably, the generator eluant added should provide about 20–50 mCi of activity. The kit was placed in a boiling water bath for 15–25 minutes to synthesize the ^{99m}Tc -TBI complex. Complex formation and purity was checked by TLC and HPLC (50 μL injection). A 250 μL injection was performed to collect the purified material. The fraction collected was subjected to rotary evaporation in vacuo to remove the solvent. The activity was determined using a dose calibrator. The complex was then dissolved in the appropriate media depending on the end-use.

I. Preparation of TBI Kits

A. Frozen Kit with FSA:

To a 25 mL vial was added the following: $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ (58 mg), formamidine sulfinic acid (FSA, $\text{H}_2\text{NC}(=\text{NH})\text{SO}_2\text{H}$, 32 mg), ethanol (2.5 mL), saline (7.5 mL), and TBI (10 μL). The solution was stirred for 15 minutes, dispensed (in 1 mL amounts) into smaller vials, stoppered, crimped, and frozen until used.

B. Dithionite Kit:

Into an appropriate vial was transferred 0.30 mL of ethanol, then 5 μL of TBI, followed by a solution of about 15 mg of sodium dithionite (sodium hydrosulfite, $\text{Na}_2\text{S}_2\text{O}_4$) in 1 mL of saline.

C. Kit using $[\text{Cu}(\text{TBI})_4]\text{BF}_4$:

This kit was prepared by combining the following: tetrakis(TBI)copper(I) tetrafluoroborate (1 mg), sodium citrate dihydrate (2.6 mg), L-cysteine hydrochloride monohydrate (1 mg), and 4 μL of a solution of stannous chloride dihydrate (prepared from 3 mg of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ in 250 μL of 1 N HCl).

Metal coordination complexes with isonitriles are well known and are described in U.S. Pat. No. 5,324,824, the contents of which are incorporated herein by reference. Examples 1–8 of this patent form metal coordination complexes of TBI.

The HPLC method for analyzing the ^{99m}Tc -TBI complex used a Zorbax® Rx C8 column (4.6 mm×150 mm) or a Zorbax® CN (4.6 mm×250 mm), a flow rate from 1.0 to 3.0 mL/min, and a gradient mobile phase from 30% 0.05 M ammonium acetate, 70% acetonitrile to 10% 0.05 M ammonium acetate, 90% acetonitrile.

The TLC method for analyzing the ^{99m}Tc -TBI complex was as follows:

A C-18 TLC plate (MKC 18F Reversed Phase TLC, Whatman #4803-110, 1×3", 200 μ thick) was prepared by drawing lines at the 1 cm and 7 cm marks. The TLC plate was spotted with the product using a capillary. The plate was eluted up to the 7 cm mark in a 4:3:2:1 solvent mixture of acetonitrile:methanol:0.5 M ammonium acetate:THF. After drying the plate for about 5 min, it was scanned using a Bioscanner (BIOSCAN

System 200 Imaging Scanner with Bioscan Auto Changer, IBM PCXT Terminal) or by an in-house radioscaner.

II. HPLC Purification of ^{99m}Tc -TBI Complex

Purification of the ^{99m}Tc -TBI complex, if needed, was achieved by injecting 250 μL of the product solution on a liquid chromatograph set up as described above for analyzing the complex and collecting the product fraction in a 10 mL round bottom flask (the collection time recorded) and the volatiles were removed by rotary evaporation. The activity in the flask was determined and recorded.

III. Preparation of the Screening Sample

About 5–10 mL of the appropriate media (see below) was added to the flask containing rotary evaporated ^{99m}Tc -TBI complex and the flask rotated on a rotary evaporator (no vacuum) for about 10 min to dissolve the complex. This solution was further diluted with the media to the desired concentration. A TLC assay was performed to ensure that the product had dissolved in the medium. For cell uptake studies the medium used was RPMI-1640, Whittaker Bioproducts, Cat. #12-702B. Concentration: 200–800 μCi per 40 mL. For washout studies the medium used was saline, concentration: 3–4 mCi per 15 mL. For imaging studies the medium used was saline/PEG (polyethylene glycol), concentration: 13–25 mCi per 0.2 mL.

The use of PEG, a solubilization aid, facilitates the removal of the ^{99m}Tc -ligand complex from the glassware used in the preparation of the complex and in its purification. It was determined that a solution of 5% PEG in saline is sufficient to remove 91% of the activity off the glassware. This amount was adequate to deliver the amount of activity needed for oncomouse imaging experiments. A solution of 5% PEG in saline has a low enough viscosity to allow for easy injection into the OncoMice™. In parallel experiments, no toxic effects from the PEG solutions were observed in mice, using concentrations below 25% (v/v).

UTILITY

^{99m}Tc -TBI was tested in tumor cell culture assays for uptake and washout and exhibited prolonged retention in tumor cells during washout. Tumor retention in vivo was studied in the c-neu OncoMouse™. A strong correlation between breast tumor retention and tissue viability was determined for ^{99m}Tc -sestamibi by dual label whole body autoradiography and histochemistry. ^{99m}Tc -TBI was directly compared with ^{99m}Tc -sestamibi for breast tumor retention in a pairwise imaging model (n=4 per compound), using planar scintigraphy with a pinhole collimator and showed significantly greater tumor retention (+133%, p<0.01) compared with ^{99m}Tc -sestamibi. These results show the unpredicted utility of ^{99m}Tc -TBI as a tumor imaging agent and the unexpected superiority of this agent compared with ^{99m}Tc -sestamibi.

All data are expressed as the mean \pm SD, with n expressed with each data set. The imaging results were tested for significance using a paired t-test. Significance was noted at p<0.05 and p<0.01 levels.

1. Uptake Assay:

The cell uptake assay protocol was developed by Delmon-Moingeon et al.¹⁰ Breast tumor cells (SKBR3) were incubated in media over a 2 hr time course with each test sample. This line has been identified as having high membrane potential and has been characterized for uptake of ^{99m}Tc -sestamibi. Any compound that displays poor uptake in this isolated cell assay would not be expected to achieve high tumor levels in vivo. The first time point (10 min.) was used to compare compounds, as this was felt to represent the non-equilibrium kinetics of delivery experienced in vivo.

^{99m}Tc -TBI exhibited a similar pattern of uptake in all 3 cell lines tested. The results are given in Tables 1–3.

TABLE 1

| Uptake (%) of ^{99m}Tc -complexes in SKBR3 breast tumor cells.* | | | |
|--|------------|------------|------------|
| Complex Ligand | 10 minutes | 20 minutes | 60 minutes |
| MIBI | 1.8 | 4.5 | 17.2 |
| TBI | 71.1 | 68.1 | 67 |

*Results are expressed as cell uptake (% of total). Results are given as the average of two assays. Variance ranged from 5–20%.

TABLE 2

| Uptake (%) of ^{99m}Tc -complexes in A549 lung tumor cells.* | | | |
|---|------------|------------|-----------|
| Complex Ligand | 10 minutes | 20 minutes | 60 minute |
| MIBI | 0.7 | 2.5 | 7.3 |
| TBI | 49.8 | 45.3 | 43.1 |

*Results are expressed as cell uptake (% of total). Results are given as the average of two assays. Variance ranged from 5–20%.

TABLE 3

| Uptake (%) of ^{99m}Tc -complexes in HBL100 nontransformed breast cells.* | | | |
|--|------------|------------|------------|
| Complex Ligand | 10 minutes | 20 minutes | 60 minutes |
| MIBI | 0.9 | 3.4 | 8.8 |
| TBI | 61.3 | 62.4 | 64.3 |

*Results are expressed as cell uptake (% of total). Results are given as the average of two assays. Variance ranged from 5–20%.

2. Washout Assay:

Two cell lines are grown on cover slips: SKBR3 human breast tumor with known high membrane potential, and an epithelial cell line (CV1) of low membrane potential. Breast tumor cells (SKBR3) and normal epithelial cells (CV-1) are grown on cover slips (5×10^5 cells) and incubated for 60 min with 100 μCi of ^{99m}Tc -isonitrite. The slips are then incubated for 120 min in nonisotopic medium with repeated rinses. ^{99m}Tc activity remaining on the slips is determined at 0, 0.5, 1, 1.5, and 2 hr. Results are expressed as the ratio of tumor/normal ^{99m}Tc activity at each of the times. Values are the mean of 4 slips per cell line.

TABLE 4

| Complex | Retention of ^{99m}Tc -isonitrites in an adherent cell assay | | | | |
|---------|---|-----|----|-----|----|
| | Time (hr) | | | | |
| Ligand | 0 | 0.5 | 1 | 1.5 | 2 |
| MIBI | 38 | 36 | 34 | 29 | 26 |
| TBI | 12 | 24 | 31 | 35 | 37 |

The washout assay characterizes the retention of compounds having gained access to the cell. A significant feature of this assay is that each cover slip was given a cell count at the end of the assay, and results were corrected for actual cell density. Because of high nonspecific binding to the coverslips, early times during washout are not meaningful, and so actual uptake and pharmacokinetics during the first phase of washout are not available. The results, however, are useful in predicting prolonged retention of compounds after blood levels have cleared.

3. Whole Body Autoradiography (in vivo assay):

The test compound was given i.v. to a transgenic c-neu mouse (OncoMouseTM). This mouse has been genetically constructed to spontaneously produce breast tumors. The tumors develop with the same cribriform pattern as observed in human tumors and have a similar pattern of blood supply. This model is superior to a xenograft model for testing a tumor viability imaging agent, since (a) delivery to the tissue is via a capillary system that originated with the tumor rather than secondarily to implanted cells or minces and (b) the tumor cells grow in a pattern and environment representative of that seen in humans, rather than the undifferentiated mass typical of a xenograft.

Female c-neu oncomice bearing breast adenocarcinomas >0.5 cm in diameter were injected i.v. with 1–3 mCi of ^{99m}Tc -TBI and 5 μCi of C-14 2-deoxy-D-glucose. The mice were sacrificed at 30 min post injection by CO_2 inhalation. The carcass was embedded and frozen in embedding medium and 20 μ frozen sections were obtained in a cryotome. Autoradiograms of sections and standards were obtained on Kodak SB5 X-ray film. Adjacent sections (5 μ) were obtained and stained with hematoxylin and eosin (H&E). Images were digitized on a LOATS video-based computerized densitometer, and regions of interest were obtained (% ID/g).

4. Pairwise imaging in the c-neu oncomouse:

The pairwise model was designed to directly compare the images of ^{99m}Tc -TBI with ^{99m}Tc -sestamibi. The same mouse was imaged at two separate times within 96 hr of each other with the test compound at one time and ^{99m}Tc -sestamibi at the other. The order of test and reference compound injected were random, but each study included at least an $n=2$ in each direction.

Female c-neu oncomice (18–30 g) and FVB wildtype mice were used in the pairwise studies. Mice with breast tumors between 1–15 mm were selected for imaging. Animals were anesthetized with sodium pentobarbital (IP) at a dose of 80 mg/kg. Tumors were measured with dial calipers and recorded on mouse templates. The tail was immersed in hot water for 1–2 min, wiped with alcohol, and injected via the tail vein (28 gauge insulin needle) with 5–2 mCi (0.15mL) of prepared ^{99m}Tc -TBI. The mouse was secured in a supine position on the dissection board with limbs and head extended to expose the chest area for optimal imaging of breast tumors. All image acquisitions were performed using a Picker Digital Dyna Gamma Camera, a Siemens MicroDelta terminal/MAXDELTA system, and a custom-made 1 mm pinhole collimator mounted on the gamma camera. The general static acquisition protocol was employed, using an acquisition matrix of 256x256 pixels, in word mode. The mouse was placed at a distance of 3 cm from the surface of the dissection board to the bottom of the collimator. The anterior view of the upper torso of the animal was acquired at each time point. Consecutive images were collected starting at 10 min post injection. Six 10 min images were collected at the 3 cm distance and one 10 min image was collected of the whole body at 15 cm to determine any tail vein activity. The mouse was observed at each ten min interval for movement and administered additional anesthesia if necessary. Total activity injected was determined by measuring the syringe before and after injection, then corrected for decay back to the time of injection. The pairwise images within each study were normalized for injected dose and regions of interest were taken over breast tumors and the heart. The mean ratio of ^{99m}Tc -TBI to ^{99m}Tc -sestamibi in the tumor was reported.

The results of the pairwise imaging screen are shown in Table 5. ^{99m}Tc -TBI exhibited a significant increase in tumor

uptake (+133%, $p < 0.01$) compared with ^{99m}Tc -sestamibi. The half lives were also calculated for the washout of ^{99m}Tc -isonitriles from SKBR3 cells. Although the kinetics were biphasic only the second phase was measureable (FIG. 4 and Table VI). ^{99m}Tc -TBI had a 6-fold increase in $t_{1/2}$ (6-fold longer retention) compared with ^{99m}Tc -sestamibi.

TABLE 5

| Paired imaging and tumor cell washout kinetics (t _{1/2}) of test compounds | | | | |
|---|--------------------------------|--|--|----------------------------------|
| Complex Ligand | # Animals Imaged (# Tumors) | Mean of Tumor Ratio Test/ ^{99m}Tc -sestamibi +/- Std Dev | | 1/2 life SKBR3 Tumor Cells |
| MIBI | 6 (14) | 1 | | 120.5 |
| TBI | 6 (14) | 1.33 +/-0.43** | | 656.0 |

** $p < .01$

The c-neu OncoMouse™ is a useful preclinical screen for imaging breast tumors. In combination with the paired imaging model, it offers considerable potential in testing new classes of compounds for utility as tumor imaging agents.

^{99m}Tc -TBI had significantly increased tumor uptake and retention in vivo, relative to ^{99m}Tc -sestamibi. Thus, ^{99m}Tc -TBI has excellent potential as a tumor imaging agent.

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

What is claimed as new and desired to be secured by Letter Patent of United States is:

1. A method of diagnosing breast tumors, comprising:
 - (a) administering parenterally to a mammal an effective amount of a composition comprising an imaging agent selected from ^{99m}Tc -tertiary-butyl isonitrile complex and $^{186/188}\text{Re}$ -tertiary-butyl isonitrile complex and a pharmaceutically acceptable carrier; and,
 - (b) radioimaging the mammal to determine whether a breast tumor is present.
2. The method of claim 1, wherein the imaging agent is ^{99m}Tc -tertiary-butyl isonitrile complex.
3. The method of claim 1, wherein the imaging agent is $^{186/188}\text{Re}$ -tertiary-butyl isonitrile complex.
4. The method of claim 1, wherein the pharmaceutical carrier is saline.
5. The method of claim 1, wherein the pharmaceutical carrier is water.
6. The method of claim 1, wherein the composition used is formed from a sterile, non-pyrogenic, kit, comprising:
 - (a) a predetermined quantity of tertiary-butyl isonitrile;
 - (b) a solubilization aid; and,
 - (c) a predetermined quantity of a reducing agent.
7. The method of claim 6, wherein the solubilization aid (b) is selected from glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monooleate, polysorbates, Pluronics, and lecithin.
8. The method of claim 7, wherein the solubilization aid (b) is selected from polyethylene glycol and Pluronics.
9. The method of claim 8, wherein the solubilization aid (b) is polyethylene glycol.
10. The method of claim 6, wherein the tertiary-butyl isonitrile (a) is in the form of a metal complex, wherein said metal is selected from Cu, Mo, Pd, Co, Ni, Cr, Ag, Rh and Zn.
11. The method of claim 10, wherein the metal is Cu.
12. The method of claim 6, wherein the reducing agent (c) is stannous chloride.

13. The method of claim 6, wherein components (a), (b), and (c) are contained in a vial.

14. A method of radioimaging breast tumors, comprising:

(a) administering parenterally to a mammal an effective amount of a composition comprising an imaging agent selected from ^{99m}Tc -tertiary-butyl isonitrile complex and $^{186/188}\text{Re}$ -tertiary-butyl isonitrile complex and a pharmaceutically acceptable carrier; and,

(b) radioimaging the mammal after allowing sufficient time for the composition to localize in a breast tumor present in the mammal.

15. The method of claim 14, wherein the imaging agent is ^{99m}Tc -tertiary-butyl isonitrile complex.

16. The method of claim 14, wherein the imaging agent is $^{186/188}\text{Re}$ -tertiary-butyl isonitrile complex.

17. The method of claim 14, wherein the pharmaceutical carrier is saline.

18. The method of claim 14, wherein the pharmaceutical carrier is water.

19. The method of claim 14, wherein the composition used is formed from a sterile, non-pyrogenic, kit, comprising:

(a) a predetermined quantity of tertiary-butyl isonitrile;

(b) a solubilization aid; and,

(c) a predetermined quantity of a reducing agent.

20. The method of claim 19, wherein the solubilization aid (b) is selected from glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monooleate, polysorbates, Pluronics, and lecithin.

21. The method of claim 20, wherein the solubilization aid (b) is selected from polyethylene glycol and Pluronics.

22. The method of claim 21, wherein the solubilization aid (b) is polyethylene glycol.

23. The method of claim 22, wherein the tertiary-butyl isonitrile (a) is in the form of a metal complex, wherein said metal is selected from Cu, Mo, Pd, Co, Ni, Cr, Ag, Rh and Zn.

24. The method of claim 23, wherein the metal is Cu.

25. The method of claim 19, wherein the reducing agent (c) is stannous chloride.

26. The method of claim 19, wherein components (a), (b), and (c) are contained in a vial.

27. The method of claim 1, wherein the composition has an activity of from about 1 to 100 mCi.

28. The method of claim 27, wherein the composition has an activity of from about 5 to 50 mCi.

29. The method of claim 1, wherein the composition contains a pharmaceutically acceptable filler.

30. The method of claim 29, wherein the filler is mannitol.

31. The method of claim 13, wherein the vial contains a pharmaceutically acceptable filler.

32. The method of claim 31, wherein the filler is mannitol.

33. The method of claim 31, wherein the components in the vial are lyophilized.

34. The method of claim 14, wherein the composition has an activity of from about 1 to 100 mCi.

35. The method of claim 34, wherein the composition has an activity of from about 5 to 50 mCi.

36. The method of claim 14, wherein the composition contains a pharmaceutically acceptable filler.

37. The method of claim 36, wherein the filler is mannitol.

38. The method of claim 26, wherein the vial contains a pharmaceutically acceptable filler.

39. The method of claim 38, wherein the filler is mannitol.

40. The method of claim 38, wherein the components in the vial are lyophilized.

* * * * *



US006200658B1

(12) **United States Patent**
Walther et al.

(10) Patent No.: **US 6,200,658 B1**
(45) Date of Patent: **Mar. 13, 2001**

(54) **METHOD OF MAKING A HOLLOW, INTERIORLY COATED GLASS BODY AND A GLASS TUBE AS A SEMI-FINISHED PRODUCT FOR FORMING THE GLASS BODY**

40 08 405 C1 7/1991 (DE) .
94 04 753 U 7/1994 (DE) .
44 38 359 A1 5/1996 (DE) .
296 09 958 U 10/1996 (DE) .
196 29 877
C1 3/1997 (DE) .

(75) Inventors: **Marten Walther**, Engelstadt; **Michael Spallek**, Burkhardt Danielzik, both of Ingelheim; **Martin Heming**; **Johannes Segner**, both of Stromberg, all of (DE)

(73) Assignee: **Schott Glas**, Mainz (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/234,168**

(22) Filed: **Jan. 19, 1999**

(30) **Foreign Application Priority Data**

Jan. 20, 1998 (DE) 198 01 861

(51) Int. Cl.⁷ **B27N 22/00**

(52) U.S. Cl. **428/34.4; 428/34.5; 428/34.6; 138/145; 138/146**

(58) Field of Search **428/34.4, 34.5, 428/34.6; 135/145, 146**

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,314,772 4/1967 Poole et al. .
4,882,209 * 11/1989 Maruyama .
5,154,943 10/1992 Etzkorn et al. .

FOREIGN PATENT DOCUMENTS

39 24 830 A1 2/1991 (DE) .

OTHER PUBLICATIONS

"Entalkalisierung Von Na₂O-CAO . . .", von Schaefer et al, Glastechn. 54(1981), Nr. 8, pp. 247-256. (No month).

"Packaging of Sensitive Parental Drugs in Glass Containers . . ." by M. Walther, Pharmaceutical Technology Europe, May 1996, vol. 8, Nr. 5., pp. 22-27.

* cited by examiner


Primary Examiner—Timothy M. Speer


(74) Attorney, Agent, or Firm—Michael J. Striker

(57) **ABSTRACT**

Numerous applications for hollow glass bodies made from low melting glass material require an increase in the chemical resistance of the interior surface of the glass body. In order to avoid a disadvantageous de-alkalizing process the hollow glass body must be provided with an interior coating in a comparatively expensive prior art process. In an improved process according to the invention a glass tube acting as a semifinished product from which the hollow glass body is made is provided with an interior coating of oxide material, preferably SiO₂, Al₂O₃, TiO₂ or mixtures thereof, having a predetermined coating thickness according to the required chemical resistance or working conditions for forming the glass body and then the hollow glass body is made from the glass tube. The coating is advantageously provided by means of a PICVD process.

9 Claims, 1 Drawing Sheet





METHOD OF MAKING A HOLLOW, INTERIORLY COATED GLASS BODY AND A GLASS TUBE AS A SEMI-FINISHED PRODUCT FOR FORMING THE GLASS BODY

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a method of making a hollow, interiorly coated glass body from a glass tube made of a low melting glass material and acting as semifinished product or intermediate product.

The invention also relates to a glass tube made from low melting glass material and acting as a semifinished product for forming a hollow glass body with an interior coating having a high chemical resistance or inertness.

2. Prior Art

Low melting glass materials, such as borosilicate glasses or calcium, sodium glasses, corrode in a known manner on contact with water or other liquids. Particularly water withdraws sodium ions from glass.

Thus it is necessary for numerous applications to increase the chemical resistance of the glass bodies, which are formed from this type of low melting glass, especially hollow glass bodies formed from glass tubes.

Hollow glass bodies, which require an increased chemical resistance for the interior surface, are, for example, those used

- for chemical plant structures,
- for flow meters for chemically reactive media,
- for analytical purposes (e.g. burette tubes, titration cylinders, etc.),
- for reagent glasses for special purposes,
- for sheathing of measuring electrodes in reactive media,
- for illumination purposes, e.g. halogen lamps,
- for discharge lamps,
- for components used for biotechnology reactors, and
- as containers for medicinal purposes (e.g. ampoules, bottles, injector devices, cylindrical ampoules, etc.).

The latter mentioned applications are of special significance.

It is indeed known to make glass tubes from silica glass (quartz glass, SiO₂ glass) as a semifinished product for forming hollow glass bodies, which have a very high chemical resistance. Those glass tubes are however very expensive because of the high melting point of the SiO₂ glass. Furthermore they can only be made with limited optical quality and are less suitable for mass production. These tubes may be formed with only very special apparatus since, on the one hand, their forming temperatures are very high and, on the other hand, the temperature interval in which their formation is possible is very small.

Semifinished glass tubes made from silica glass thus may not be of sufficient quality and are uneconomical for mass applications.

Predominantly low melting glasses, e.g. borosilicate glasses or calcium-sodium glasses, are used for large-scale glass products. These may advantageously be formed as tubes economically.

For example these glasses include the following: Duran®-borosilicate glass (Schott Glas), Fiolax®klar (Schott Glas), Fiolax®braun (Schott Glas) and Kimble N 51 A (Fa. Kimble).

The compositions of these glasses made in the form of glass tubing are tabulated in the following Table I.

TABLE I

| GLASS COMPOSITIONS IN % by WEIGHT* | | | | | | | | |
|------------------------------------|------------------|-------------------------------|--------------------------------|-------------------|------------------|-----|-----|-----|
| GLASS | SiO ₂ | B ₂ O ₃ | Al ₂ O ₃ | Na ₂ O | K ₂ O | MgO | CaO | BaO |
| 1 | 69 | 1.0 | 4 | 12.5 | 3.5 | 2.5 | 5 | 2 |
| 2 | 69 | 1.0 | 4 | 12.5 | 3.5 | 2.5 | 5 | 2 |
| 3 | 69 | 1.0 | 4 | 12.5 | 3.5 | 2.5 | 5 | 2 |
| 4 | 70 | 1.0 | 4 | 12.5 | 3.5 | 2.5 | 5 | 2 |
| 5 | 69 | 1.0 | 4 | 12.5 | 3.5 | 2.5 | 5 | 2 |
| 6 | 69 | 1.0 | 4 | 12.5 | 3.5 | 2.5 | 5 | 2 |
| 7 | 75 | 11 | 5 | 7 | | | 1.5 | 0.5 |
| 8 | 75 | 11 | 5 | 7 | | | 1.5 | 0.5 |
| 9 | 80 | 13 | 2.5 | 3.5 | 0.5 | | | |
| 10 | 70.8 | 8 | 5.5 | 7 | 1.5 | | 1 | 2 |
| 11 | 70.8 | 8 | 5.5 | 7 | 1.5 | | 0.5 | 2 |
| 12 | 72.8 | 11 | 7 | 7 | 1 | | 1 | |
| 13 | 73.3 | 10 | 6 | 6 | 3 | | 0.5 | |
| 14 | 74.3 | 10 | 6 | 8 | 1 | | | |

*balance to 100% consists of other elements (for No. 10 and No. 11 Fe₂O₃ and TiO₂ which together are 3.5%)

It is known to increase the chemical resistance of these glass tubes made from low melting glass by a method in which the glass surface is chemically leached out. A suitable reactive gas (SO₂, (NH₄)₂SO₄ or HCl) is conducted through the still warm glass tube, which leads to a surface reaction and a reduction in the alkali content at the surface.

This type of dealkalinizing process is, e.g., described in H. A. Schaeffer, et al, Glastechn. Ber. 54, Nr. 8. pp. 247 to 256. The disadvantage of this process is that predominantly toxic gasses are used, whereby the glass surface can contain traces of these reactive reaction gases after this chemical treatment and the glass surface structure is damaged which leads to an increased surface area and to an increase in reactive sites on the surface. Furthermore the use of these reactive gases is undesirable from an environmental standpoint and due to worker safety consideration. With many of the suggested gases corrosive by-products arise, which react strongly with metal apparatus parts. Furthermore particles can be released from the porous damaged surfaces during shaping or forming of this type of leached out glass tube. Also a washing process for removal of reaction products is necessary prior to use of the leached out glass tube. This washing process necessitates a drying and disposal of reaction products, i.e. the costs increase for making the semifinished glass tubes.

An additional process for dealkalinizing low melting glass by fluorination by means of fluoro-acids, which has the same main disadvantages as the above-described process, is described in U.S. Pat. No. 3,314,772.

In order to avoid the disadvantages of dealkalinizing process it is also known to provide a tubular glass container from low melting glass material, which operates as a packaging device for pharmaceutical materials, having a silicon dioxide (SiO₂) layer on its interior surface, which has the same inertness as a quartz glass surface (M. Walther, "Packaging of sensitive parenteral drugs in glass containers with a quartz-like surface", in Pharmaceutical Technology Europe, May, 1996, Vol. 8, Nr. 5, pp. 22 to 27.

The coating of the interior surface of the formed glass body occurs by chemical deposition of an oxide coating from the gas phase, especially by means of a vacuum-assisted plasma CVD process (PECVD=plasma enhanced chemical vapor deposition), in particular by means of a pulsed plasma process (PICVD=plasma impulse chemical vapor deposition).

This PECVD or PICVD method for coating of an interior of a hollow body, especially made from plastic, is known from German Patent Documents DE 196 29 877 and DE-Z

"Multilayer Barrier Coating System produced by Plasma-impulse Chemical Vapor Deposition (PRCVD)" by M. Walther, M. Hemming, M. Spallek, in "Surface and Coatings Technology" 80, pp. 200 to 205 (1966).

In the known case (DE 296 09 958 U1) the finished containers, i.e. the glass bodies themselves, are interiorly coated. Because of that each glass container, must be subjected to an expensive coating process, adapted to its form.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a simple and economical method of making a hollow glass body made from a low melting glass material.

It is another object of the present invention to provide a semifinished glass tube for making the hollow, interiorly coated glass body of the invention.

These objects and others which will be made more apparent hereinafter are attained in a process of the above-described type for making a hollow, interiorly coated glass body from a glass tube made of low melting glass material and acting as a semifinished product or intermediate.

According to the invention this process includes the steps of:

coating the interior surface of the semifinished glass tube with an oxide material to form an interior coating having a coating thickness which is adapted to the subsequent shaping or working conditions required for making the glass body and the chemical resistance requirements of the glass body, and

making the glass body from the interiorly coated semifinished glass tube.

The glass tube according to the invention acting as the semifinished product or intermediate for making the glass body has an interior surface provided with a coating of oxide material whose coating thickness adapted to the subsequent shaping or working conditions required for making the glass body and the chemical resistance requirements of the glass body.

Glass tubes are prepared with the methods of the invention whose chemical resistance is largely maintained after a working or shaping process. These working or shaping processes can include constrictions, melting and shaping at the ends of the glass tubes, e.g. in order to be able to join them together, to connect them, to close them, etc.

The invention not only concerns the manufacture of hollow glass bodies with a high degree of shaping, i.e. the forming of such glass bodies, but also those glass bodies with a comparatively reduced degree of shaping or working, e.g. cylindrical bodies, which are made from semifinished articles by hot forming or cold forming, e.g. a drawing process, and which must be still worked only on their opposite ends. These glass bodies include, for example, an injector cylinder, e.g. according to German Patent Document DE 39 24 830 A1 or a reagent container according to German Patent Document DE 94 04 753.7 U1 or an injector cylinder open on both ends, which is closed by two stoppers and on which a needle attachment can be provided.

Because of the invention it is also possible to prepare glass tubes with increased interior chemical resistance so that the predominant part of the surface of the entire system is provided with a high chemical resistance after a possible shaping process, while a comparatively smaller area portion is left with a lesser chemical resistance. Exemplary applications include: glass tubes which are used in biotechnology and are used with media which is absorbed in standard glass surfaces, containers for medical purposes in which the total

ion leach out from the container plays an important role, (e.g. for dispensing alkali and other metal ions).

When comparatively long glass tubes used as intermediate products for making the glass bodies are coated in a working process, the interiorly coated glass bodies can be made in a simple and economical manner, since the coating can be predominantly maintained after shaping. A semifinished product (or semiproduct) is a half-finished product, an article that is an intermediate between the raw material and the finished product, which however is obtained by subsequently performing different finishing steps.

Methods for interiorly coating glass tubes are known in themselves. These glass tubes are used, e.g., as pre-forms for optical fibers for transmitting light and information. Two optically different types of glass are made in the interior of a tube, which however in order to be able to be drawn out as a fiber must have very similar thermal properties (softening and shaping temperatures) and expansion coefficients.

In the known cases however glass tubes made from low melting glass material cannot act as semifinished products for forming or shaping of hollow glass bodies having an interior coating made of oxide material for increasing the chemical resistance of the glass interior surface.

The coating thickness of the oxide material is adjusted to the working or shaping conditions and the chemical resistance requirements. Both these requirements interfere with each other to some extent, since a thick coating guarantees a great chemical resistance, but impairs or prevents satisfactory working or shaping. A definite specific concrete statement of the required thickness range for the coating is not possible, but instead the coating thickness must be adapted to the particular shaping or working process being performed and to the chemical resistance requirements.

A typical coating thickness range is according to a preferred embodiment of the invention in a range of from 1 nm to 500 nm or from about 1 nm to 500 nm. The coating thickness also depends on the material selected for the coating.

According to a preferred embodiment of the invention the following oxides may be used, among others, as coating materials: SiO_2 , Al_2O_3 , TiO_2 or mixtures thereof.

The following methods are especially preferred for coating the interior surface of semifinished glass pipe.

Methods for coating from the liquid phase (Sol Gel coating), for example, are described in H. Bach, D. Krause, "Thin Films on Glass", Springer Verlag, Berlin (1997).

Methods are known for precipitation from supersaturated solutions.

Sputtering methods, even when their use for pipe-like substrates is complicated, can be used, since sputtering process are direct processes.

Advantageously CVD processes (CVD=chemical vapor deposition) can be used for making of the semifinished glass tube. The coating is produced at elevated temperatures (i.e. higher than room temperature) in so-called thermal CVD methods. These methods can be used directly during the manufacture of the glass tube after the known drawing process. For this purpose the coating gas is used as supporting air/blowing air. The coating gas decomposes in a predetermined temperature range in the glass tube and forms a coating on its interior tube surface. A suitable similar method can of course be employed which is independent of the manufacture of the glass tube however re-heating of the glass tube is then required. The subsequent heating can occur

5

by different methods, e.g. direct heating, heating with a laser and so forth. It is also possible to reduce the coating temperature when light radiation is used for activation/production of the active coating conditions. Advantageously the deposition of the oxide coating material can occur from the gas phase, from the coating gas, by means of a vacuum-assisted plasma CVD method, the so-called PECVD processes (plasma enhanced chemical vapor deposition). The PECVD process is described in various references. Diverse embodiments are used with different energy input in the low frequency range (e.g. 40 kHz), in the middle frequency range (e.g. 13.56 MHz) up to the microwave range (2.45 GHz and above). Examples are found in G. Janzen, "Plasma-technik(Plasma Engineering)", Hutig-Verlag, Heidelberg, 1992.

In a preferred embodiment which is especially advantageous a modified PECVD method, the so-called PICVD process (plasma-impulse-CVD process) is used, which provides a high uniformity for large-scale coated substrates. The PICVD technology is known in the patent literature from German Patent Document DE 40 08 405 C1 and from U.S. Pat. No. 5,154,943 and for example used for producing barrier layers on plastic containers (German Patent Document DE 44 38 359 A1). This technology uses pulsed plasmas for deposition of coatings from the respective coating gases.

BRIEF DESCRIPTION OF THE DRAWING

The objects, features and advantages of the invention will now be illustrated in more detail with the aid of the following description of the preferred embodiments, with reference to the accompanying sole figures which is a cross-sectional view through an apparatus for interior coating of a glass tube according to the method of the invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The coating apparatus shown in the figure operates according to the PICVD process. A glass tube section 1 made from low melting glass material, such as borosilicate or calcium-sodium glass, which is to be coated inside and which acts as a semifinished product or intermediate for making the interiorly coated, hollow glass body, is held in a container 2 in a vacuum-tight manner by means of the seals 3.

The glass tube section 1 has a length of 1500 mm and an interior diameter of 12 mm in the embodiment shown in the drawing.

The length of the glass tube section to be coated conforms to the dimensions of the available coating apparatus.

The interior of the glass tube section 1 is connected to one end of a vacuum system comprising a pump 4 and a valve 5.

A microwave supply device 6 comprising electrodes (antennas) passes through the container 2. Microwave radiation is coupled impulse-wise into both ends of the microwave supply device 6 by means of suitable microwave blocks 6a, 6b. The duration of the microwave pulse is in a range of from 0.1 to 10 ms.

The interior of the glass tube is connected at its other end with a gas supply apparatus 7. The gas, in which a plasma is ignited, typically oxygen, is conducted into the interior of the glass tube by means of this gas supply apparatus via a mass flow regulator 8. Another gas, the reaction gas,

6

required for forming the coating, is also conducted into the interior of the glass tube by means of this glass supply apparatus via another mass flow regulator 9.

The reaction gas typically is a metal-organic reaction gas, such as siloxane, preferably hexamethyldisiloxane (HMDSO), tetramethyldisiloxane, titaniumtetraisopropoxide (TIPT) or silazane, from which the coating on the inside of the glass tube 1 is formed by selection of the suitable pulse duration. The pulse duration is an additional parameter, which also influences the composition of the deposited coating.

The coating process is controlled in a known manner by an unshown process controller.

First the entire tube system is evacuated and then the process pressure is controlled so that it is about 1 mbar. After that the oxygen is conducted into the system with flow of 135 standard cubic units. After 5 s 2.45 GHz microwave radiation at a power of 1 kW is input to both sides of the glass tube 1 by means of the electrodes of the microwave supply device. Because of that the plasma ignites inside the glass tube 1 and the glass tube is heated to a process temperature of 250° C. When this temperature is reached, a mass flow of 5 standard cubic units of reaction gas, preferably HMDSO, is supplied under control of the mass flow regulator 9, so that a gas mixture of oxygen and HMDSO is found inside the glass tube 1. Now a microwave power of 1.5 kW is coupled impulse-wise into the plasma inside the glass tube 1 by means of the electrodes 6, whereby the molecules of the reaction gas are cracked. The cracking products produced diffuse to the closest surface,—here the glass tube to be coated—and in due course form the desired coating. In the interval between pulses until the following pulse is ignited, which is in a range of from 10– to 100 ms, the consumed reaction gases are removed from the vacuum chamber by means of the vacuum stages 4,5 in the same manner as a two cycle motor and replaced by fresh reaction gas and oxygen.

In this manner a coating with the thickness of 5 nm can be deposited in 2 s.

The properties of the coating substantially depend on the parameters "pulse duration" and "reaction gas concentration". Generally harder coatings are deposited at small concentrations and with long pulses, which cause a substantial increase in inertness. At high concentrations and with short pulses, softer layers are deposited.

Basically a multilayer coating can be produced. Furthermore as soon as a sufficient layer thickness is obtained for the first layer, the reaction gas required to produce it is replaced by a reaction gas for the second layer. To produce a non-discontinuous or non-sharp transition between both layers, a mixture of both reaction gases can be conducted into the apparatus for a predetermined time interval. For a uniform transition the proportion of the first reaction gas can be gradually reduce and at the same time the proportion of the second reaction gas can be continuously increased to its nominal value.

Additionally or instead of oxygen as the plasma gas or gas for producing the plasma, other gases for producing a plasma which are known, such as argon, helium, hydrogen or nitrogen. Other gases for producing the plasma are described, e.g., in the book, "Plasma-Technik(Plasma Engineering)", by Schade, Verlag Technik (Engineering Press), GmbH, Berlin, 1990.

EXAMPLE

Four samples with coating thicknesses of 0.5 nm, 1 nm, 5 nm and 50 nm are prepared by variation of the coating time

with the apparatus shown in the drawing. Ampoules are formed as glass bodies from the coated semifinished glass tubes. Both the unfinished glass tube samples and the finished ampoules, including an uncoated sample, were tested with the help of atomic absorption spectroscopy for limiting values according to ISO 4802, Part II, after autoclaving with steam.

The results for the Na leach out after one hour are shown in Table II hereinbelow, for the tubing in column 2 and for the ampoules in column 4.

Also the workability or formability of the ampoules from the crude or unfinished tube samples was evaluated qualitatively. These evaluations are also shown in Table II in column 3 for the respective coating thickness. The results show that the glass tube with a coating thickness of 50 nm is not workable or formable and the glass tube with a coating thickness of 5 nm has poor workability or formability and is unsatisfactory for making the ampoules.

TABLE II

MEASUREMENTS OF THE PROPERTIES AND WORKABILITY OF SEMIFINISHED GLASS TUBE SAMPLES AND AMPOULES MADE FROM THEM

| COATING THICKNESS | NA LEACH OUT (TUBE), PPM | WORKABILITY (TO AMPOULES) | NA-LEACH OUT (10 ML), PPM |
|-------------------|--------------------------|---------------------------|---------------------------|
| Uncoated | 0.54 ppm | Good | 0.96 ppm |
| 0.5 nm | 0.11 ppm | Good | 0.21 ppm |
| 1 nm | 0.04 ppm | Good | 0.12 ppm |
| 5 nm | <0.01 ppm | Poor | 0.30 ppm |
| 50 nm | <0.01 ppm | Impossible | No measurement Possible |

The results in Table II shows that the blocking action of the coating increases with increasing coating thickness, but at the same time ampoules cannot be made if the coating is too thick. An optimum coating thickness with minimum sodium leach out is expected between a coating thickness of 1 nm and 5 nm with this coating system.

The disclosure in German Patent Application 198 01 861.4-45 of Jan. 20, 1998 is incorporated here by reference. This German Patent Application describes the invention described hereinabove and claimed in the claims appended hereinbelow and provides the basis for a claim of priority for the instant invention under 35 U.S.C. 119.

While the invention has been illustrated and described as embodied in a method of making a hollow, interiorly coated glass body and glass tube as semifinished product for forming the glass body, it is not intended to be limited to the details shown, since various modifications and changes may be made without departing in any way from the spirit of the present invention.

Without further analysis, the foregoing will so fully reveal the gist of the present invention that others can, by applying current knowledge, readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic or specific aspects of this invention.

What is claimed is new and is set forth in the following appended claims.

We claim:

1. A glass tube made from low melting glass material and acting as a semi-finished product or intermediate for making a hollow, interiorly coated glass body with an interior coating increasing a chemical resistance of said hollow, interiorly coated glass body, said glass body being formed by shaping or working, wherein said glass tube has an interior surface and a coating of oxide material on said interior surface, and said coating has a predetermined coating thickness, whereby required shaping or working conditions for making said glass body from said glass tube and chemical resistance requirements for said glass body are met.

2. The glass tube as defined in claim 1, wherein said coating thickness is in a range from 1 nm and 500 nm or from about 1 nm to 500 nm.

3. The glass tube as defined in claim 1, wherein said coating thickness is between about 1 to 5 nm.

4. The glass tube as defined in claim 1, wherein said oxide material comprises SiO_2 , Al_2O_3 , TiO_2 or mixtures thereof.

5. The glass tube as defined in claim 1, wherein said coating is provided on the interior surface of the glass tube by a method comprising a chemical vapor deposition process and including passing a mixture of a reaction gas and oxygen through the glass tube and forming a microwave discharge in the mixture in the glass tube, said reaction gas comprising hexamethyldisiloxane, tetramethyldisiloxane, titanium tetraisopropoxide or silazane.

6. A glass tube with an interior oxide coating, said glass tube with said interior oxide coating being made by a method comprising the steps of:

a) providing a glass tube consisting of a low melting glass material and having an interior surface; and

b) coating said interior surface of said glass tube provided in step a) with an oxide selected from the group consisting of SiO_2 , Al_2O_3 and TiO_2 or with a mixture of at least two members selected from the group consisting of SiO_2 , Al_2O_3 and TiO_2 to form the interior oxide coating with a thickness of from about 1 nm to 500 nm;

whereby said glass tube with said interior oxide coating is an intermediate product for making a hollow, interiorly coated glass body from said glass tube by shaping or working so that said hollow, interiorly coated glass body has an increased chemical resistance.

7. The glass tube as defined in claim 6, wherein said thickness is from about 1 nm to 5 nm.

8. The glass tube as defined in claim 6, wherein said method comprises chemical vapor deposition (CVD) of said interior oxide coating on said interior surface from a gas phase by vacuum-assisted plasma enhanced chemical vapor deposition or plasma impulse chemical vapor deposition.

9. The glass tube as defined in claim 6, wherein said method comprises depositing said oxide coating from a liquid phase according to a sol-gel process or from a supersaturated solution.

* * * * *